<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Atypon//DTD Atypon JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables v1.0.0 20120831//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName Atypon-archive-oasis-article1.dtd?><?SourceDTD.Version 1.0.0?><?ConverterInfo.XSLTName atyponoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Respir. Crit. Care Med</journal-id><journal-id journal-id-type="publisher-id">ajrccm</journal-id><journal-title-group><journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">1073-449X</issn><issn pub-type="epub">1535-4970</issn><publisher><publisher-name>American Thoracic Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7258628</article-id><article-id pub-id-type="pmid">32311297</article-id><article-id pub-id-type="publisher-manuscript">202004-1153ED</article-id><article-id pub-id-type="doi">10.1164/rccm.202004-1153ED</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorials</subject></subj-group></article-categories><title-group><article-title>COVID-19: First Do No Harm</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waterer</surname><given-names>Grant W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rello</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8527-4195</contrib-id><name><surname>Wunderink</surname><given-names>Richard G.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><aff id="aff1"><label><sup>1</sup></label>School of Medicine<break/>University of
Western Australia<break/>Crawley, Western Australia, Australia</aff><aff id="aff2"><label><sup>2</sup></label>Northwestern University Feinberg School of
Medicine<break/>Chicago, Illinois</aff><aff id="aff3"><label><sup>3</sup></label>Centro de Investigaci&#x000f3;n Biomedica en
Red (CIBERES)<break/>Instituto de Salud Carlos III<break/>Madrid,
Espa&#x000f1;a</aff><aff id="aff4"><label><sup>4</sup></label>Vall d&#x02019;Hebron Institute of Research
(VHIR)<break/>Barcelona, Spain<break/>and</aff><aff id="aff5"><label><sup>5</sup></label>CHU N&#x000ee;mes<break/>Universit&#x000e9;
Montpellier-N&#x000ee;mes<break/>N&#x000ee;mes, France</aff></contrib-group><pub-date pub-type="epub-ppub"><day>1</day><month>6</month><year>2020</year><!--string-date: June 1, 2020--></pub-date><!--Fake epub and ppub dates generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="epub"><day>1</day><month>6</month><year>2020</year><!--string-date: June 1, 2020--></pub-date><pub-date pub-type="ppub"><day>1</day><month>6</month><year>2020</year><!--string-date: June 1, 2020--></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>6</month><year>2020</year><!--string-date: June 1, 2020--></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub-ppub"/>. --><volume>201</volume><issue>11</issue><fpage>1324</fpage><lpage>1325</lpage><permissions><copyright-statement>Copyright &#x000a9; 2020 by the American Thoracic
Society</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This article is open access and distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivatives License 4.0
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>). For
commercial usage and reprints, please contact Diane Gern (<email xlink:href="dgern@thoracic.org">dgern@thoracic.org</email>).</license-p></license></permissions><self-uri content-type="pdf" xlink:href="rccm.202004-1153ED.pdf"/><counts><fig-count count="0"/><table-count count="0"/><page-count count="2"/></counts></article-meta></front><body><p content-type="flushleft">In his book &#x0201c;Of the Epidemics&#x0201d; Hippocrates advises
physicians that they must &#x0201c;have two special objects in view with regard to
disease, namely, to do good or to do no harm&#x0201d; (<xref rid="bib1" ref-type="bibr">1</xref>). Facing the challenge of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic, this advice remains as pertinent now as it was over
2,400 years ago. In response to the 1919 Spanish flu pandemic, physicians in desperation
turned to the antimalarial quinine (<xref rid="bib2" ref-type="bibr">2</xref>). It is
disappointing that 100 years later, despite the emphasis on evidence-based medicine, the
same strategy was adopted, owing to the highly emotional need to treat patients with
&#x0201c;something.&#x0201d;</p><p>Faced with a new disease, numbers of patients that have in many cases vastly overwhelmed
healthcare resources, and no available effective treatment, an extraordinary array of
experimental therapies have been given to critically ill patients, often in combination.
Whether this approach has harmed more patients that it has helped remains to be seen.
Desperate times are felt to justify desperate measures. However, in this issue of the
<italic>Journal</italic>, the case series by Du and colleagues (pp. <ext-link ext-link-type="doi" xlink:href="10.1164/rccm.202003-0543OC">1372&#x02013;1379</ext-link>) (<xref rid="bib3" ref-type="bibr">3</xref>)
demonstrates that access to basic critical care support, not experimental therapies, is
the most important determinant of the high mortality reported in some SARS-CoV-2 series.
Despite acute respiratory distress syndrome in 74% and shock in 81%, only 21% of cases
received invasive mechanical ventilation.</p><p>Many physicians across the world are recommending treatments even while researchers and
regulators claim that the evidence of benefit is limited, and therapies should be tested
in a randomized controlled trial. These physicians believe that the chance of potential
benefit outweighs the chance of harm. However, safety concerns may be significantly
underestimated since most of these drugs have never been properly studied in critically
ill patients. For example, many of the experimental therapies used are potentially
cardiotoxic, including hydroxychloroquine, ritonavir, lopinavir, IFN &#x003b1;-2-&#x003b2;,
azithromycin, and methylprednisolone. As myocarditis is reported as a potential
complication of SARS-CoV-2, if all these agents are used in combination, is it a
surprise that very high rates of cardiac complications occur, such as the 60% incidence
of arrhythmia reported in the case series from Du and colleagues (<xref rid="bib3" ref-type="bibr">3</xref>) in this issue and by others (<xref rid="bib4" ref-type="bibr">4</xref>)? IFNs are generally proinflammatory and may be deleterious in patients
with hyperinflammation with high plasma IL-6. Anti&#x02013;IL-6 monoclonal antibodies
have been associated with cytomegalovirus reactivation, episodes of bacterial septic
shock, and bowel perforation, particularly when combined with high-dose corticosteroids
(<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>). Many of these experimental agents have pharmacologic interactions with a
large list of drugs commonly used in critical care, hampering overall management and
increasing the risk of toxicity. High-dose steroids, associated with superinfections,
such as invasive pulmonary aspergillosis, increased mortality in influenza pneumonia
(<xref rid="bib7" ref-type="bibr">7</xref>), and worse outcomes in the 2009
influenza A pandemic (<xref rid="bib8" ref-type="bibr">8</xref>), were used in 75% of
fatal cases in the series by Du and colleagues (<xref rid="bib3" ref-type="bibr">3</xref>), and 74% of critical cases in the multicenter study of Feng and
colleagues (<xref rid="bib9" ref-type="bibr">9</xref>), also in this issue of the
<italic>Journal</italic> (pp. <ext-link ext-link-type="doi" xlink:href="10.1164/rccm.202002-0445OC">1380&#x02013;1388</ext-link>). Like
hydroxychloroquine, high-dose corticosteroids may be associated with delirium,
agitation, and psychosis that often is complicating the weaning of intubated patients
with SARS-CoV-2 infection. Patients and their families have a clear right to be informed
of the risks of all these experimental therapies so they can provide informed consent
for compassionate use. That this is routinely occurring seems unlikely.</p><p>Treating all patients with the same therapy regardless of stage of disease or clinical
phenotype is also perilous, and properly conducted trials are necessary to select
patient characteristics associated with a beneficial response. It is very clear that
patients are presenting with different clinical phenotypes causing respiratory failure
(<xref rid="bib10" ref-type="bibr">10</xref>), both with and without evidence of
&#x0201c;cytokine storm&#x0201d; (<xref rid="bib11" ref-type="bibr">11</xref>). It would
clearly be unreasonable to expect patients with such different phenotypes to respond
similarly to the same experimental interventions. The recent report on compassionate use
of remdesivir among 53 patients with severe SARS-CoV-2 infection showed an improvement
in oxygen support in 36 (68%) whereas 8 (15%) showed worsening; clinical improvement was
less frequent among intubated patients (hazard ratio, 0.33) and patients older than 70
years (hazard ratio, 0.29) (<xref rid="bib12" ref-type="bibr">12</xref>). With serious
adverse events reported in 23% of patients (<xref rid="bib12" ref-type="bibr">12</xref>), personalized therapy is clearly going to be required.</p><p>Another serious problem with routine use of unproven agents for SARS-CoV-2 is that
clinical equipoise is lost and an experimental agent becomes <italic>de facto</italic>
standard of care, potentially seriously compromising the ability to do
placebo-controlled trials. Inability to complete a controlled trial because of loss of
clinical equipoise is a two-edged sword. Even if the intervention has true benefit, it
is unlikely detractors will be convinced and lives will be lost because the treatment is
still not given. If the intervention has adverse effects not revealed because of the
absence of a placebo arm, then lives may be lost because it continues to be used. If
experimental agents are given in combination, attribution of effects, both beneficial
and adverse, to one of them becomes nearly impossible, given the significant variability
in critical care outcomes as a baseline.</p><p>Unquestionably, much of the pathogenesis and optimal therapy of SARS-CoV-2 remains
unknown, but we strongly believe that it is critically important that, when faced with
uncertainty, clinicians stick to standards of care that are proven and robust. The
SARS-CoV-2 pandemic is an opportunity to learn how to treat patients and test therapies
at the same time (<xref rid="bib13" ref-type="bibr">13</xref>). Trials of experimental
therapies are certainly justified, but only in properly conducted randomized controlled
trials where their risks and benefits can be accurately assessed, and certainly not in
untried combinations which greatly increase the risk of harm.</p><p>Concerns that results from conventional trials can take years is proving false with
hundreds of patients enrolled within 6 weeks in at least two SARS-CoV-2&#x02013;specific
clinical trials. Adaptive multicenter trials with interim analyses have the ability to
determine if an intervention is superior to placebo and adjust the standard of care and
move on to test new therapies in rapid succession. Once a new intervention has become
standard of care, it can be tested against alternatives or combinations of drugs. For
sites that don&#x02019;t have the capacity to generate local trials, participation in
platform trials like REMAP-CAP (The Randomised, Embedded, Multi-Factorial, Adaptive
Platform Trial for Community-acquired Pneumonia) (<xref rid="bib14" ref-type="bibr">14</xref>) should be encouraged.</p><p>In summary, we believe that the widespread use of clearly experimental therapies being
reported in patients with SARS-CoV-2 is dangerous and unjustified. There is a real risk
that mortality rates are higher than they need to be because of toxic, ineffective
therapy. Clinicians must not succumb to the impulse to &#x0201c;do something else&#x0201d;
but instead stick to evidence-based therapies and, if possible, enroll their patients
into adaptive clinical trials. SARS-CoV-2 is likely to be a problem for years, and we
need to develop precision approaches based on high-quality clinical data as fast as we
can. Equally, and unfortunately, SARS-CoV-2 will not be the last serious viral pneumonia
epidemic humanity faces, and only by having a scientific approach this time can we avoid
going back to 1919-era desperation treatments the next time we are faced with this
challenge.</p></body><back><fn-group><fn><p>R.G.W. is supported by NIH award U19AI135964.</p></fn><fn><p>Originally Published in Press as DOI: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.202004-1153ED">10.1164/rccm.202004-1153ED</ext-link> on April 20, 2020</p></fn><fn fn-type="financial-disclosure"><p><underline><bold><ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.202004-1153ED/suppl_file/disclosures.pdf">Author disclosures</ext-link></bold></underline> are available with
the text of this article at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><label>1. </label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>F</given-names></name></person-group>
<source>The genuine works of Hippocrates</source>
<publisher-loc>London</publisher-loc>
<publisher-name>The Sydenham Society</publisher-name>
<year>1849</year>
</mixed-citation></ref><ref id="bib2"><label>2. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shors</surname><given-names>T</given-names></name><name><surname>McFadden</surname><given-names>SH</given-names></name></person-group>
<article-title>1918 influenza: a Winnebago County, Wisconsin
perspective</article-title>
<source><italic>Clin Med Res</italic></source>
<year>2009</year>
<volume>7</volume>
<fpage>147</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">19889943</pub-id></mixed-citation></ref><ref id="bib3"><label>3. </label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Mu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><etal><italic>et al</italic></etal></person-group><article-title>Clinical features of 85 fatal cases of COVID-19 from
Wuhan: a retrospective observational study</article-title><source><italic>Am J Respir Crit Care Med</italic></source><year>2020</year><volume>201</volume><fpage>1372</fpage>&#x02013;<lpage>1379</lpage><pub-id pub-id-type="pmid">32242738</pub-id></mixed-citation></ref><ref id="bib4"><label>4. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kochi</surname><given-names>AN</given-names></name><name><surname>Tagliari</surname><given-names>AP</given-names></name><name><surname>Forleo</surname><given-names>GB</given-names></name><name><surname>Fassini</surname><given-names>GM</given-names></name><name><surname>Tondo</surname><given-names>C</given-names></name></person-group>
<article-title>Cardiac and arrhythmic complications in patients with
COVID-19</article-title>
<source><italic>J Cardiovasc Electrophysiol</italic></source>
<comment>[online ahead of print] 9 Apr 2020; DOI: 10.1111/jce.14479</comment>
</mixed-citation></ref><ref id="bib5"><label>5. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogata</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name><name><surname>Higa</surname><given-names>S</given-names></name><name><surname>Yoshizaki</surname><given-names>K</given-names></name></person-group>
<article-title>IL-6 inhibitor for the treatment of rheumatoid arthritis: a
comprehensive review</article-title>
<source><italic>Mod Rheumatol</italic></source>
<year>2019</year>
<volume>29</volume>
<fpage>258</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="pmid">30427250</pub-id></mixed-citation></ref><ref id="bib6"><label>6. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komura</surname><given-names>T</given-names></name><name><surname>Ohta</surname><given-names>H</given-names></name><name><surname>Nakai</surname><given-names>R</given-names></name><name><surname>Seishima</surname><given-names>J</given-names></name><name><surname>Yamato</surname><given-names>M</given-names></name><name><surname>Miyazawa</surname><given-names>M</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Cytomegalovirus reactivation induced acute hepatitis and gastric
erosions in a patient with rheumatoid arthritis under treatment with an
anti-IL-6 receptor antibody, tocilizumab</article-title>
<source><italic>Intern Med</italic></source>
<year>2016</year>
<volume>55</volume>
<fpage>1923</fpage>
<lpage>1927</lpage>
<pub-id pub-id-type="pmid">27432105</pub-id></mixed-citation></ref><ref id="bib7"><label>7. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moreno</surname><given-names>G</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A</given-names></name><name><surname>Reyes</surname><given-names>LF</given-names></name><name><surname>Gomez</surname><given-names>J</given-names></name><name><surname>Sole-Violan</surname><given-names>J</given-names></name><name><surname>D&#x000ed;az</surname><given-names>E</given-names></name><etal><italic>et al</italic></etal></person-group>
<collab>GETGAG Study Group</collab>
<article-title>Corticosteroid treatment in critically ill patients with severe
influenza pneumonia: a propensity score matching study</article-title>
<source><italic>Intensive Care Med</italic></source>
<year>2018</year>
<volume>44</volume>
<fpage>1470</fpage>
<lpage>1482</lpage>
<pub-id pub-id-type="pmid">30074052</pub-id></mixed-citation></ref><ref id="bib8"><label>8. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ni</surname><given-names>YN</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>BM</given-names></name><name><surname>Liang</surname><given-names>ZA</given-names></name></person-group>
<article-title>The effect of corticosteroids on mortality of patients with
influenza pneumonia: a systematic review and meta-analysis</article-title>
<source><italic>Crit Care</italic></source>
<year>2019</year>
<volume>23</volume>
<fpage>99</fpage>
<pub-id pub-id-type="pmid">30917856</pub-id></mixed-citation></ref><ref id="bib9"><label>9. </label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal><italic>et al</italic></etal></person-group><article-title>COVID-19 with different severities: a multicenter study
of clinical features</article-title><source><italic>Am J Respir
Crit Care Med</italic></source><year>2020</year><volume>201</volume><fpage>1380</fpage>&#x02013;<lpage>1388</lpage><pub-id pub-id-type="pmid">32275452</pub-id></mixed-citation></ref><ref id="bib10"><label>10. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Coppola</surname><given-names>S</given-names></name><name><surname>Cressoni</surname><given-names>M</given-names></name><name><surname>Busana</surname><given-names>M</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Chiumello</surname><given-names>D</given-names></name></person-group>
<article-title>COVID-19 does not lead to a &#x0201c;typical&#x0201d; acute
respiratory distress syndrome</article-title>
<source><italic>Am J Respir Crit Care Med</italic></source>
<comment>[online ahead of print] 30 Mar 2020; DOI:
10.1164/rccm.202003-0817LE</comment>
</mixed-citation></ref><ref id="bib11"><label>11. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name></person-group>
<article-title>The pathogenesis and treatment of the &#x02018;Cytokine
storm&#x02019; in COVID-19</article-title>
<source><italic>J Infect</italic></source>
<comment>[online ahead of print] 10 Apr 2020; DOI:
10.1016/j.jinf.2020.03.037</comment>
</mixed-citation></ref><ref id="bib12"><label>12. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grein</surname><given-names>J</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Diaz</surname><given-names>G</given-names></name><name><surname>Asperges</surname><given-names>E</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>Compassionate use of remdesivir for patients with severe
Covid-19</article-title>
<source><italic>N Engl J Med</italic></source>
<comment>[online ahead of print] 10 Apr 2020; DOI:
10.1056/NEJMoa2007016</comment>
</mixed-citation></ref><ref id="bib13"><label>13. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name></person-group>
<article-title>Optimizing the trade-off between learning and doing in a
pandemic</article-title>
<source><italic>JAMA</italic></source>
<comment>[online ahead of print] 30 Mar 2020; DOI:
10.1001/jama.2020.4984</comment>
</mixed-citation></ref><ref id="bib14"><label>14. </label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Berry</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>RJ</given-names></name><name><surname>Al-Beidh</surname><given-names>F</given-names></name><name><surname>Arabi</surname><given-names>Y</given-names></name><name><surname>van Bentum-Puijk</surname><given-names>W</given-names></name><etal><italic>et al</italic></etal></person-group>
<article-title>The randomized embedded multifactorial adaptive platform for
community-acquired pneumonia (REMAP-CAP) study: rationale and
design</article-title>
<source><italic>Ann Am Thorac Soc</italic></source>
<comment>[online ahead of print] 8 Apr 2020; DOI:
10.1513/AnnalsATS.202003-192SD</comment>
</mixed-citation></ref></ref-list></back></article>